Nasdaq Halts Statera Biopharma, Inc.

Rhea-AI Summary

On August 25, 2022, trading in Statera Biopharma, Inc. (Nasdaq: STAB) was halted by Nasdaq at 11:01:52 A.M. ET for "additional information requested". The last sale price before the halt was $0.215. Trading will remain suspended until the company fulfills Nasdaq's information request.

Investors are advised to check the Nasdaq website for further developments regarding the company.

Positive

• None.

Negative

• Trading halt may indicate regulatory concerns or issues with the company.
• Last sale price of $0.215 suggests poor market performance and potential investor uncertainty.

NEW YORK, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market^® (Nasdaq: NDAQ) announced that trading was halted today in Statera Biopharma, Inc. (Nasdaq: STAB) at 11:01:52 A.M. Eastern Time for "additional information requested" from the company at a last sale price of $0.215.

Trading will remain halted until Statera Biopharma, Inc. has fully satisfied Nasdaq’s request for additional information.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotes^SM on the Nasdaq^® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

Nasdaq Media Contact:

Sophia Weiss
sophia.weiss@nasdaq.com

NDAQO

 

FAQ

Why was Statera Biopharma's trading halted on August 25, 2022?

Trading was halted for 'additional information requested' by Nasdaq.

What is the last sale price of Statera Biopharma before the trading halt?

The last sale price was $0.215.

When will Statera Biopharma resume trading?

Trading will resume once Statera Biopharma satisfies Nasdaq's request for additional information.

What stock symbol is associated with Nasdaq in this press release?

The stock symbol mentioned is NDAQ.